Your daily source for AI news, tools reviews, and practical guides to artificial intelligence
OpenAI employs its advanced AI reasoning capabilities to aid physicians in diagnosing rare genetic diseases in children, resulting in 18 new confirmed diagnoses of previously unresolved cases.
OpenAI’s latest GPT-5.4 model, integrated with Molecule.one’s platform, demonstrates near-autonomous AI capabilities by improving a challenging medicinal chemistry reaction, marking a milestone in AI-driven drug discovery.
Sam Altman has propelled OpenAI from an experimental AI lab to a dominant commercial force, but this evolution highlights the AI industry’s deepening trust challenges.
Yann LeCun, Meta’s AI chief, warns that leading AI labs such as OpenAI and Anthropic face a ‘big bubble explosion’ due to investor subsidies masking high operational costs.
Noam Shazeer, a key figure behind Google’s Gemini and foundational transformer research, moves to OpenAI after a brief return to Google, signaling a strategic talent shift in the AI race.
Microsoft has emerged as the sole American AI vendor selling OpenAI’s GPT models to major Chinese internet firms, navigating geopolitical and IP risks that OpenAI and Anthropic avoid.
OpenAI’s transformation from a research lab to a market-dominant AI powerhouse reveals a central tension: can trust survive amid rapid commercialization and Microsoft’s influence?
OpenAI’s AI reasoning model has enabled researchers to diagnose 18 previously unsolved rare childhood genetic diseases, showcasing AI’s growing role in healthcare.
OpenAI has introduced three new Academy courses designed to help professionals develop practical AI abilities, create repeatable workflows, and leverage AI agents at work, signaling a strategic push to empower users amid the accelerating AI adoption.
OpenAI has onboarded Transformer co-inventor Noam Shazeer and former AI policy official Dean Ball, strengthening its leadership ahead of its anticipated IPO.